Insider Trading November 19, 2026 07:07 PM

Nektar Therapeutics R&D Chief Offloads Shares to Cover Tax Obligations

Jonathan Zalevsky's sale of 192 shares was tied to RSU vesting, not a discretionary trade, as NKTR hovers near its 52-week low.

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
NKTR

Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky sold 192 shares of company stock on November 17, 2026, at a weighted average price of $35.85, generating $6,883. The transaction was not a discretionary trade but was made to satisfy tax withholding requirements upon the vesting of restricted stock units. Following the sale, Zalevsky directly holds 9,378 shares. The disclosure comes as NKTR shares trade at $32.54, just above their 52-week low of $32.51, having fallen 12.7% over the past week and 53% over the last six months. The company recently reported third-quarter results with a narrower-than-expected adjusted loss per share of $1.63 versus analysts' $2.08 estimate, though revenue of $9.39 million missed the $10.31 million consensus. Nektar held $952.9 million in cash and investments as of September 30, 2026, which is expected to fund operations into the third quarter of 2028 and support the Phase 3 ZENITH AD trials for atopic dermatitis. The company has also advanced its REZPEG treatment into Phase III studies for atopic dermatitis and alopecia areata.

Nektar Therapeutics R&D Chief Offloads Shares to Cover Tax Obligations
NKTR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • The sale by Nektar's Chief R&D Officer was a non-discretionary transaction to cover tax withholding on vesting restricted stock units, not a discretionary trade.
  • NKTR shares are trading near their 52-week low of $32.51, having fallen 12.7% in the past week and 53% over six months.
  • The company's third-quarter revenue missed expectations, but its cash position of $952.9 million is expected to fund operations into the third quarter of 2028.

Nektar Therapeutics (NASDAQ:NKTR) disclosed that its Chief R&D Officer, Jonathan Zalevsky, disposed of 192 shares of the company's common stock on November 17, 2026. The shares were sold at prices ranging from $35.57 to $36.31, with a weighted average sale price of $35.85, resulting in total proceeds of $6,883.

The filing indicates that the transaction was not a discretionary trade by Zalevsky. Instead, the shares were sold to cover required tax withholding obligations associated with the vesting of restricted stock units. After the sale, Zalevsky directly holds 9,378 shares of Nektar Therapeutics common stock.

The disclosure arrives at a challenging moment for the company's stock. NKTR shares are currently trading at $32.54, only marginally above their 52-week low of $32.51. Over the past week, the stock has declined 12.7%, and it has fallen 53% over the last six months, according to InvestingPro data.

InvestingPro Tips highlight that the company is quickly burning through cash and that analysts do not anticipate profitability this year. These are two of 12 key insights available to subscribers. For deeper analysis, investors can access NKTR's comprehensive Pro Research Report, part of the platform's coverage of over 1,400 US equities.

In other recent news, Nektar Therapeutics reported its third-quarter financial results, revealing a narrower-than-expected loss. The company posted an adjusted earnings per share loss of $1.63, surpassing analysts' expectations of a $2.08 loss. However, Nektar's revenue of $9.39 million fell short of the anticipated $10.31 million.

As of September 30, 2026, the company held $952.9 million in cash and investments, which is expected to sustain operations into the third quarter of 2028. This cash reserve is intended to support Nektar through the Phase 3 ZENITH AD trials for atopic dermatitis. Despite the earnings beat, investors seemed more concerned with the revenue miss and the extended timeline to commercialization.

Additionally, the company has advanced its REZPEG treatment into Phase III studies for atopic dermatitis and alopecia areata. These developments are crucial for Nektar as it continues to focus on its pipeline progress over immediate sales.

The insider sale, while small in dollar terms, provides a window into the routine financial planning of a key executive at a company navigating a critical period. The stock's proximity to its 52-week low and the substantial decline over the past six months underscore the pressures facing Nektar as it balances pipeline advancement with financial sustainability.

Risks

  • Nektar is quickly burning through cash, and analysts do not anticipate profitability this year, which could pressure the stock further.
  • The company's revenue fell short of expectations in the third quarter, and investors are concerned about the extended timeline to commercialization.
  • The stock is trading just above its 52-week low, indicating potential for further declines if negative sentiment persists.

More from Insider Trading

nLIGHT Accounting Chief Offloads 180 Shares Under Pre-Set Trading Plan Nov 19, 2026 Saba Capital Adds to BNY Mellon Strategic Municipals Stake with $430,818 Purchase Nov 19, 2026 AEye Director Husby Adds 35,860 Shares Near 52-Week Low Nov 19, 2026 Magnite Director Paul Caine Offloads $500,853 in Shares Nov 19, 2026 Intuitive Machines Insider Sale Tied to RSU Tax Withholding as Shares Retreat Nov 19, 2026